leisure time -WSS

leisure time

author：explore 2025-10-01 05:40:14 - browse：82797

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： NIH fellows want a pay raise. Will that mean less money for grants?

Wikipedia

entertainment

WSS

Global cancer cases to surge 77% by 2050, WHO report says

Living with Fabry disease, a condition that causes chronic pain

Readout Newsletter: Amgen, Regeneron, BGI Group and more

AstraZeneca stays mum on Medicare drug pricing negotiations

NIH fellows want a pay raise. Will that mean less money for grants?

A single Democrat is willing to weaken Medicare negotiation power

entertainment

leisure time

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

The CDC's new social media misinformation war

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Activists slam private health insurers over coverage restrictions

Palantir health business leans on meeting customers’ needs

Alkermes shareholders re

Top private equity targets in 2023: cardiology, clinical trials, lasers

Peter Hotez and the public health issue of online harassment

Unique patient identifier: Experts argue the benefits, pitfalls

hotspot

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

A protest over insulin prices is seen as a fight for life

Leqembi, other new Alzheimer’s drugs require better biomarkers

NIH fellows want a pay raise. Will that mean less money for grants?

Unique patient identifier: Experts argue the benefits, pitfalls

Wikipedia

Wikipedia

entertainment

leisure time